A very low number of circulating basophils is predictive of a poor response to omalizumab in chronic spontaneous urticaria

2. Katoh N, Kraft S, Wessendorf JH, Bieber T. The high-affinity IgE receptor (FcepsilonRI) blocks apoptosis in normal human monocytes. J Clin Invest. 2000;105(2):183-190. 3. Martinez FO, Gordon S, Locati M, Mantovani A. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: New molecules and patterns of gene expression. J Immunol. 2006;177(10):7303-7311. 4. Novak N, Peng WM, Bieber T, Akdis C. FcepsilonRI stimulation promotes the differentiation of histamine receptor 1-expressing inflammatory macrophages. Allergy. 2013;68(4):454-461. 5. Mommert S, Aslan D, Ratz L, Stark H, Gutzmer R, Werfel T. The anaphylatoxin C3a receptor expression on human M2 macrophages is down-regulated by stimulating the histamine H4 receptor and the IL-4 receptor. J Innate Immun. 2018;1-14. 6. Pellizzari G, Hoskin C, Crescioli S, et al. IgE re-programs alternatively-activated human macrophages towards pro-inflammatory anti-tumoural states. EBioMedicine. 2019;43:67-81. 7. Geiger E, Magerstaedt R, Wessendorf JH, Kraft S, Hanau D, Bieber T. IL-4 induces the intracellular expression of the alpha chain of the high-affinity receptor for IgE in in vitro-generated dendritic cells. J Allergy Clin Immunol. 2000;105(1 Pt 1):150-156. 8. Gutzmer R, Diestel C, Mommert S, et al. Histamine H4 receptor stimulation suppresses IL-12p70 production and mediates chemotaxis in human monocyte-derived dendritic cells. J Immunol. 2005;174(9):5224-5232. 9. Mommert S, Kleiner S, Gehring M, et al. Human basophil chemotaxis and activation are regulated via the histamine H4 receptor. Allergy. 2016;71(9):1264-1273.

[1]  M. Rovaris,et al.  Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients , 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.

[2]  T. Zuberbier,et al.  The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria , 2018, Allergy.

[3]  D. Larenas-Linnemann,et al.  Update on Omalizumab for Urticaria: What’s New in the Literature from Mechanisms to Clinic , 2018, Current Allergy and Asthma Reports.

[4]  C. Möbs,et al.  Functional and phenotypic analysis of basophils allows determining distinct subtypes in patients with chronic urticaria , 2017, Allergy.

[5]  P. Korošec,et al.  Basophils, high-affinity IgE receptors, and CCL2 in human anaphylaxis , 2017, The Journal of allergy and clinical immunology.

[6]  A. Giménez-Arnau,et al.  Basophil FcεRI Expression in Chronic Spontaneous Urticaria: A Potential Immunological Predictor of Response to Omalizumab Therapy. , 2017, Acta dermato-venereologica.

[7]  T. Omachi,et al.  Effect of Omalizumab on Blood Basophil Counts in Patients with Chronic Idiopathic/Spontaneous Urticaria. , 2017, The Journal of investigative dermatology.

[8]  A. Giménez-Arnau,et al.  Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria , 2017, Allergy.

[9]  M. Lawrence,et al.  Lack of basophil CD203c-upregulating activity as an immunological marker to predict response to treatment with omalizumab in patients with symptomatic chronic urticaria. , 2016, The journal of allergy and clinical immunology. In practice.